Navigation Links
Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
Date:12/13/2007

Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Relapsed

Diffuse Large B-Cell Lymphoma

COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that study centers have been initiated and are ready to enroll patients in a Phase II study of ofatumumab (HuMax-CD20(R)) to evaluate treatment of relapsed Diffuse Large B-Cell Lymphoma (DLBCL) in patients ineligible for or relapsed following a stem cell transplant. Approximately 75 patients will be enrolled in the study which is being conducted under Genmab's collaboration with GlaxoSmithKline (GSK). Genmab will receive a milestone payment of approximately DKK 87.2 million from GSK upon treatment of the first patient in the study, expected in the near future.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 receptor on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 receptor. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

"We have now expanded the ofatumumab clinical development program into a fourth disease area," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We hope ofatumumab will offer a new and effective treatment option for patients suffering from DLBCL."

About the trial

In this open label trial, each patient will receive 8 weekly infusions of ofatumumab. The first infusion will be 300 mg and the 7 subsequent infusions will be 1000 mg of ofatumumab. Disease status will be assessed 4 weeks after the last infusion and then every 3 months for a total of 24 months after treatment start according to the "Revised response criteria for malignant lymphoma." After 24 months, patients will be followed until initiation of alternative DLBCL treatment or month 60. T
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
2. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
3. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
4. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
5. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
6. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
7. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
8. Harbinger Research Initiates Coverage on HearAtLast
9. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...ould identify those who would benefit from liver s...ESDAY, Dec. 1 (HealthDay News) -- A CT scan of liv...r may help predict overall survival after chemothe...(Avastin) to cytotoxic chemotherapy has been shown...olorectal cancer and to produce better results in ...
(Date:12/1/2009)... Practitioners of any medi...nscription are breathing a sigh of relief this wee...Phone. The application, released over the holiday...anscribe voice recordings to do so quickly and sea... (PRWEB) December 1, 2009 -- The ...
(Date:12/1/2009)..., , ,, NEW YORK, Dec. 1 /P...and a global leader in the development and deliver...for the medical, scientific and academic markets, ...versal Search, our first-to-market cross-platform ...sychology lexicon, based on the American Psycholog...
(Date:12/1/2009)..., , FORT LAUDERDALE, Fla., Dec. 1 /PRNews... of patient enrollment in the randomized clinical ...g Stent (Combo Stent). ,, A prospective, random... E valuation of an ablu M inal sirolimus coat ... patients at up to 20 sites in Asia, Australia, Eu...
(Date:12/1/2009)... Montreal, December 1, 2009 A Universit de Montra...arch Center on Family Violence and Violence Agains...ffects of pornography on men. "We started our rese...onsumed pornography. We couldn,t find any," says S...professor at the School of Social Work. , "The ...
Breaking Medicine News(10 mins):Health News:CT Scan May Predict Colon Cancer Survival 2Health News:Medical and Legal Professionals Find Relief Leveraging Apple iPhone App for Dictation and Transcription 'On the Go' 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:Are the effects of pornography negligible? 2
...C., Oct. 30 It,s no secret that,companies rely he... top,talent. But best-in-class organizations have ... hiring opportunities, according to research from,...izations and, ultimately, into their,work forces. ...
..., Oct. 30 West Anaheim Medical,Center, an affilia...nstalled a state-of-the-art patient tracking and i...ent. Housed within the hospital,s MEDITECH,system,... and efficiently. This patient safety process take...
...A) Specifically aimed, stereotactic radiation may ...ter in treating benign but potentially devastatin...cording to a study by rradiation oncologists at th...ent is effective and the only way to remove the t...
...erts from the U.S Centers for Disease Control, Uni...: HIV Symposium at Association for Molecular Patho...Nov. 7, 9:00 to 10:00 am , Where: Hyatt Regency ... been concerned about HIVs ability to mutate and c...
... and analysis reveal how salaries measure up acros...LADELPHIA, Oct. 30 Case in Point Magazine announc...and Trends Survey.,Presenting professional demogra...prevailing trends. Anne Llewellyn,RN-BC, MS, BHSA,...
... Oct 30 Perrigo Company,(Nasdaq: PRGO ; TASE) to... a,quarterly dividend of $0.05 per share, payable ...November 23, 2007. The new quarterly dividend of,$...care supplier that develops,manufactures and distr...
Other Medicine News:Health News:Lessons Learned in Securing Top Talent During University Recruiting 2Health News:Hospital Launches State-of-the-Art Patient Tracking and Integrated Patient Data System 2Health News:Jefferson oncologists show focused radiation is effective as surgery against nerve tumor 2Health News:Case in Point Magazine Releases 2007 Case Management Salary and Trends Survey 2
(Date:12/1/2009)... , ATLANTA, Dec. 1 C...edical device and cardiovascular tissue processing... for 2010. ,, The Company expects total revenue...illion and $123.0 million, which includes between ...eceived from the Department of Defense in connecti...
(Date:12/1/2009)... , PISCATAWAY, N.J., Dec. 1 ...ens.com/hearing) a leading global manufacturer of ...rtnership with Quota International,s Sound Beginni...h September 2010. ,, As part of the renewed par...ide vouchers for 100 free hearing instruments to b...
(Date:12/1/2009)... , BEIJING, Dec. 1 /PRNewswire-Asia/ ...provider of biopharmaceutical products in China, a...chase order for its H1N1 vaccine, PANFLU.1(TM),fr...chnology for the national,purchase plan. Under thi...n,additional one million doses of PANFLU.1 (TM) (1...
Breaking Medicine Technology:CryoLife Provides Initial 2010 Financial Guidance 2CryoLife Provides Initial 2010 Financial Guidance 3CryoLife Provides Initial 2010 Financial Guidance 4CryoLife Provides Initial 2010 Financial Guidance 5Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government 3Nothing But Nets Delivers Anti Malaria Nets to Children and Families in Uganda 60146 1Nothing But Nets Delivers Anti Malaria Nets to Children and Families in Uganda 60146 2Nothing But Nets Delivers Anti Malaria Nets to Children and Families in Uganda 60146 3Radiation From Medical Scans Soaring 60144 1Radiation From Medical Scans Soaring 60144 2Radiation From Medical Scans Soaring 60144 3Relevant Security and bitRail Debut RevSecure Product Line 60142 1Relevant Security and bitRail Debut RevSecure Product Line 60142 2Relevant Security and bitRail Debut RevSecure Product Line 60142 3Relevant Security and bitRail Debut RevSecure Product Line 60142 4
...ntibody method for HbA1c provides outstanding accu... agreement with the HPLC method(1) , Near-patien...ur results are reliable(2) , National Glycohemog...hod, as recommended by the ADA** , , , Micr...
Advia WorkCell CDX Modular Automation
Blood Coagulation Analyzer CG Series
Cascade M Manual Coagulation Analyzer
Medicine Products: